Phase 3 Study Shows Sustained Psoriasis Responses With SSGJ-608
Key Takeaways
- Phase 3 results from a study in China with moderate-to-severe plaque psoriasis, both SSGJ-608 regimens met the coprimary week 12 efficacy endpoints.
- PASI75 response rates at week 12 were 95.1% and 93.4% with the 2 SSGJ-608 regimens, respectively, compared with 8.8% with placebo.
- Responses were maintained through week 52, and investigators reported a favorable safety profile without increased risk with longer drug exposure.
A phase 3 trial of the investigational interleukin (IL)-17A–targeting monoclonal antibody (SSGJ-608) showed high response rates through 52 weeks among adults with moderate-to-severe plaque psoriasis.
Investigators for the double-blind, placebo-controlled trial included 458 adults in the sample and randomly assigned them (2:2:1) to placebo (n = 91), SSGJ-608 80 mg every 2 weeks following a 160-mg loading dose (608A; n = 184), or SSGJ-608 160 mg every 4 weeks (608B; n = 183). PASI75 and sPGA 0/1 served as the study’s coprimary endpoints.
SSGJ-608 Meets Coprimary Psoriasis Endpoints
PASI75 was achieved by 95.1% of patients in the 608A group and 93.4% in the 608B group, compared with 8.8% receiving placebo, at Week 12. Static Physician Global Assessment (sPGA) scores of 0 or 1 were achieved by 76.1%, 67.2%, and 1.1%, respectively. Beginning at week 12, maintenance dosing was reduced to 80 mg every 4 weeks in the 608A group and 160 mg every 8 weeks in the 608B group. Patients initially receiving placebo were reallocated to one of the active-treatment regimens.
According to the results, responses remained high at week 52. PASI75 was maintained by 93.7% and 93.6% of patients in the 608A and 608B groups, respectively, while PASI90 rates were 92.6% and 92.5%. Corresponding sPGA 0/1 rates were 89.3% and 89.4%.
“SSGJ-608 showed rapid and robust clinical response at week 12 and through week 52, and was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis,” the authors concluded.
Source
Han L, et al. American Journal of Clinical Dermatology. 2026. https://doi.org/10.1007/s40257-026-01057-8